FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine and can be used for developing molecular methods of treating coronary insufficiency. For this purpose, the simulated myocardial ischemia requires experimental myocardial injections of an endotheliocyte growth factor gene in the form of the phVEGF165 vector at 50-100 mcg/cm2 of an ischemic region at an area pitch of 5 mm. 2-dimethylaminoethanol is added to the vector preparation to provide more effective myocardiocyte transfection.
EFFECT: unlike peptide growth factors requiring the regular administration, the use of a gene construct with the endotheliocyte growth factor gene introduced in a single dose according to the developed method provides the intensified myocardial construct delivery and the activation of a greater number of cells involved in angiogenesis that promotes repaired perfusion in the ischemic myocardium region.
2 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CORONARY INSUFFICIENCY | 2014 |
|
RU2572798C1 |
| METHOD OF TREATMENT OF ATOPIC DERMATITIS | 2022 |
|
RU2804005C1 |
| METHOD FOR THERAPY OF SKIN DAMAGES AND BIOTRANSPLANT THEREFOR | 2014 |
|
RU2588835C1 |
| METHOD OF INHIBITING GROWTH OF TUMOR CELLS | 2019 |
|
RU2712770C1 |
| METHOD FOR REPARATIVE ANGIOGENESIS STIMULATION AND CONNECTIVE TISSUE REGENERATION IN CASE OF ITS DAMAGE, BY THE GENETIC THERAPY METHOD USING SPECIES-SPECIFIC VEGF AND FGF2 PROTEIN FACTORS GENES IN VETERINARY MEDICINE, AND GENETIC STRUCTURE FOR IMPLEMENTATION OF METHOD | 2015 |
|
RU2614665C1 |
| OPTIMIZED NUCLEOTIDE SEQUENCE AND PHARMACEUTICAL COMPOSITIONS BASED THEREON WITH SUSTAINED VEGF TRANSGENE EXPRESSION | 2015 |
|
RU2612497C2 |
| AGENT FOR CORRECTION OF AGE CHANGES IN THE SKIN | 2019 |
|
RU2803093C2 |
| METHOD OF ANGIOGENESIS AUGMENTATION IN ISCHEMIC TISSUES AND COMBINATION DRUG FOR METHOD IMPLEMENTATION | 2015 |
|
RU2628706C2 |
| NON-INFECTIOUS FOR HUMAN ADENOVIRUS AS VECTOR FOR SUBSTITUTION GENETIC THERAPY OF ANGIOGENESIS DISORDER PROVIDING EFFECTIVE SYNTHESIS OF HUMAN ANGIOGENIN IN MAMMALIAN TRANSFECTED CELLS, METHOD FOR ANGIOGENESIS INDUCTION, METHOD FOR TREATMENT OF ISCHEMIC DISEASE, COMPOSITION FOR INDUCTION OF ANGIOGENESIS AND TREATMENT OF ISCHEMIC DISEASE | 2005 |
|
RU2321631C2 |
| CELL-BASED THERAPY OF ISCHEMIC TISSUE | 2009 |
|
RU2535966C2 |
